Shares in telehealth business Hims & Hers Health (HIMS) dropped over 6% today after reports that it and peers are marketing ...
Hims & Hers is shutting down Apostrophe, the skincare company it acquired in 2021, after a tumultuous month for the public ...
1d
Zacks Investment Research on MSNHims & Hers Stock Gains 8.6% in Three Months: How to Play It?Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term gains from the stock of late. Shares of the ...
Hims & Hers Health (HIMS) has disclosed plans to shut down Apostrophe, its acne treatment business. This change is part of ...
Hims & Hers Health would discontinue Apostrophe, its personalized acne treatments dermatology business, the company said on ...
9don MSN
Although the telemedicine company displayed blistering growth and issued robust guidance, shares of Hims & Hers (NYSE: HIMS) ...
Hims & Hers Health's revenue grew 69% YoY, boosting its outlook. See why HIMS stock’s growth potential and high implied ...
Telehealth personalized care company Hims & Hers shuttered a central part of its dermatology offering, skincare brand Apostrophe, to "simplify" its dermatology offerings and operation | Hims & Hers ...
The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents.
Hims & Hers saw a massive YTD surge, but FDA news led to a pullback. Find out why HIMS stock is still undervalued and why ...
Hims & Hers Health ( HIMS -12.79%) stock took a tumble Thursday morning, falling 9.2% through 11:40 a.m. ET on some ...
Shares of Hims & Hers Health ( HIMS) tumbled 15% yesterday after Novo Nordisk (NVO) announced it was cutting the price of its ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results